{
    "title": "AbbVie's revenue miss clouds strong Humira U.S. sales",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4164098/Drugmaker-AbbVies-quarterly-revenue-misses-estimates.html",
    "date": "2017-01-27",
    "keywords": [
        "humira",
        "company",
        "drug",
        "revenue",
        "treatment",
        "percent",
        "competition",
        "gmt",
        "grover",
        "imbruvica",
        "johnson",
        "vikiera",
        "inc",
        "majority",
        "officer",
        "price",
        "clouds",
        "email",
        "mukhopadhyayjan",
        "hepatitis",
        "c",
        "cancer",
        "therapy",
        "demand",
        "humirathe",
        "companys",
        "afternoon",
        "trading",
        "market",
        "valueabbvie",
        "focus",
        "oncology",
        "reliance",
        "halfownership",
        "inventory",
        "issue",
        "abbvie",
        "pak",
        "gilead",
        "merck",
        "forecast",
        "quarter",
        "europe",
        "dollar",
        "launch",
        "biosimilar",
        "amgen",
        "bill",
        "chase",
        "growth",
        "see",
        "anything",
        "horizon",
        "trajectory",
        "richard",
        "gonzalez",
        "callabbvie",
        "coverage",
        "month",
        "year",
        "payer",
        "scrutiny",
        "pricing",
        "intensifiesabbvie",
        "callthe",
        "estimate",
        "thomson",
        "share",
        "mukhopadhyay",
        "bengaluru",
        "editing",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}